Targeting Autophagy in Multiple Myeloma

ISBN-13: 9783659812545 / Angielski / Miękka / 2015 / 96 str.

Dai Yun;Grant Steven

Opis

Apoptosis (Type I) and autophagy (Type II) represent two major forms of programmed cell death. Numerous anticancer agents employed in standard chemotherapy or novel targeted therapy induce both apoptosis and autophagy. Of note, a cytoprotective autophagic response often counteracts apoptosis triggered by such agents, potentially contributing to drug-resistance. Mechanistically, autophagy and apoptosis share molecular regulatory mechanisms primarily governed by the Bcl-2 family proteins. However, since autophagy acts as the double-edge sword in cancer, whether autophagy should be inhibited or activated in cancer treatment remains the subject of debate. Here we report a) a novel autophagy-targeted strategy that targeting the adaptor SQSTM1/p62 induces "inefficient" autophagy due to cargo-loading failure and converts cytoprotective autophagic response to apoptosis via the BH3-only protein NBK/Bik (Part 1); and b) a new mechanism for acquired drug-resistance in which the BH3-only protein Bim acts as a dual-agent regulating both autophagy and apoptosis (Part 2).

O autorze

Yun Dai, MD/PhD, MS in Clinical and Translational Sciences, Associate Professor, Medicine, Massey Cancer Center, Virginia Commonwealth University, USA; Aoqing Tang Professor, the First Hospital of Jilin University, China. The principal focus of his research is to understand cancer biology and to develop precision targeted therapy against cancer.